Furthermore, the use of polo-like kinase 1(PLK1) inhibitors alongside cisplatin in the treatment of esophageal squamous cell carcinoma has been shown to enhance the therapeutic response (34, 74). The gene discussed is PLK1; the disease is esophageal squamous cell carcinoma.